Baird Downgrades BioMarin Pharmaceutical to Neutral From Outperform, Cuts Price Target to $72 From $104
Baird Downgrades BioMarin Pharmaceutical to Neutral From Outperform, Cuts Price Target to $72 From $104
贝尔德将BioMarin Pharmaceutical的评级从跑赢大盘下调至中性，将目标股价从104美元下调至72美元
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间